Results 51 to 60 of about 10,942 (165)

Reversible Eltrombopag‐Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1‐Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Hypoplastic myelodysplastic syndrome (MDS) often overlaps clinically with aplastic anemia and frequently involves clonal hematopoiesis. Thrombopoietin receptor agonists (TPO‐RAs), including eltrombopag, are increasingly used to treat cytopenias in hypoplastic marrow failure syndromes; however, their long‐term effects on clonal dynamics and ...
Kyoko Yoshihara, Ikuo Matsuda, Yasuhito Nannya, Mami Samori, Naru Tomigaki, Saki Takahashi, Chisato Ohe, Satoshi Yoshihara   +7 more
wiley   +1 more source

PNH with FLNA mutation patients (1998_2019)

, 2019
All documented PNH patients with FLNA mutations from 1998 to 2019 were collected, and the mutation sites and characteristics of nine clinical systems were ...
Sun, H
core   +3 more sources

Paroxysmal nocturnal hemoglobinuria and thrombosis

Акушерство, гинекология и репродукция
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematopoiesis disorder caused by a somatic mutation in the PIGA (phosphatidylinositol glycan, class A) gene, resulting in deficiency of glycosylphosphatidylinositol (GPI)anchored ...
A. R. Khisamieva, A. R. Oskolkova, V. O. Bitsadze, J. Kh. Khizroeva, N. A. Makatsariya, M. V. Tretyakova, N. R. Gashimova, K. N. Grigoreva, D. V. Blinov, J.-Ch. Gris, I. Elalamy, G. Gerotziafas, A. D. Makatsariya   +12 more
doaj   +1 more source

Pegcetacoplan Delivers Real‐World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real‐World Clinical and Patient‐Reported Outcomes

European Journal of Haematology, Volume 117, Issue 4, Page 799-813, October 2026.
ABSTRACT Aims Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired, non‐malignant haematological disorder that, if left untreated, can lead to significant morbidity. This systematic literature review (SLR) summarized real‐world evidence (RWE) for pegcetacoplan, a complement 3/3b inhibitor (C3i) available since 2021.
Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi, Vikte Lionikaite, Elisabetta Metafuni   +4 more
wiley   +1 more source

Role of pH and thrombin in the PNH hemolytic system

, 1960
The effect of bovine thrombin on pH-hemolysis curves in paroxysmal nocturnal hemoglobinuria (PNH) was studied. Symmetrical curves demonstrating accentuation of PNH hemolysis by thrombin were obtained.
Joseph V. Auditore, John M. Flexner, Robert C. Hartmann   +2 more
core   +1 more source

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco‐Hematology

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 1000-1007, October 2026.
ABSTRACT Objectives Digital morphology (DM) systems assisted by artificial intelligence are increasingly being introduced into hematology laboratories; however, data on their performance in routine clinical practice for bone marrow aspirates (BMA) remain limited.
Gina Zini, John Marra, Elena Rossi, Silvia Bellesi, Nicoletta Pelliccioni, Giuseppe d'Onofrio, Patrizia Chiusolo   +6 more
wiley   +1 more source

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

PLoS ONE, 2020
BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser   +19 more
doaj   +1 more source

A Population‐Based Study on Childhood Aplastic Anemia—Incidence, Outcomes, and Health‐Related Quality of Life

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background Childhood aplastic anemia (AA) is a rare disease, and both the disease itself and its treatment cause significant morbidity. We aimed to determine the contemporary incidence of childhood AA in Finland, to compare the clinical characteristics of AA against inherited bone marrow failure syndromes (IBMFS) and refractory cytopenia of ...
Lauri‐Matti Kulmala, Riitta Niinimäki, Tytti Pokka, Anu Huurre, Liisa Järvelä, Sauli Palmu, Tuuli Pöyhönen, Pauliina Utriainen, Henri Aarnivala   +8 more
wiley   +1 more source

Pregnancy in PNH: another eculizumab baby.

, 2010
Pregnancy in PNH: another eculizumab ...
Notaro R, Santachiara R, COLUCCIO, Valeria, TORELLI, Giuseppe, Leonardi G, Luzzatto L., MARASCA, Roberto   +6 more
core   +1 more source

PRC2.1 Coordinates Peri‐Nucleolar H3K27me3‐Enriched Heterochromatin Organization and NPM1 Pentamerization to Maintain Nucleolar Integrity

Advanced Science, Volume 13, Issue 51, 14 September 2026.
PRC2.1(PCL2)‐coordinated H3K27me3‐enriched PNH establishes a spatial scaffold crucial for nucleolar integrity. As a crucial coordinator, PCL2 links PRC2.1 to chromatin organization and NPM1 assembly. This network‐based model reveals how chromatin modifications and nucleolar components cooperatively maintain nucleolar architecture, revealing novel ...
Lina Zhu, Wenqin Wang, Shuyun Chen, Gangyi Zhu, Zhen Wu, Yue Gu, Jingwen Xiong, Xu Zhang, Heng Liu, Kyoichi Isono, Youming Zhang, Jingjing Cao, Xiangzhi Li   +12 more
wiley   +1 more source